TIMI I

OBJECTIVE: To compare the efficacy of tissue plasminogen activator and streptokinase for
reperfusion of the infarct-related artery in ST elevation myocardial infarction.

View/Download
___________________________________________________________________________________

1. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932-6.
   | Abstract | Request Reprints |
   
   
2. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. Hillis LD, Borer J, Braunwald E, et al. J Am Coll Cardiol 1985;6:957-62.
   | Abstract | Request Reprints |
   
   
3. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Williams DO, Borer J, Braunwald E, et al. Circulation 1986;73:338-46.
   | Abstract | Request Reprints |
   
   
4. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Chesebro JH, Knatterud G, Roberts R, et al. Circulation 1987;76:142-54.
   | Abstract | Request Reprints |
   
   
5. Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction. Gore JM, Roberts R, Ball SP, Montero A, Goldberg RJ, Dalen JE. Am J Cardiol 1987;59:1234-8.
   | Abstract | Request Reprints |
   
   
6. Comparison of monoplane and biplane assessment of regional left ventricular wall motion after thrombolytic therapy for acute myocardial infarction. Holmes DR, Jr., Bove AA, Nishimura RA, et al. Am J Cardiol 1987;59:793-7.
   | Abstract | Request Reprints |
   
   
7. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. Mueller HS, Rao AK, Forman SA. J Am Coll Cardiol 1987;10:479-90.
   | Abstract | Request Reprints |
   
   
8. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. J Clin Invest 1987;79:1642-7.
   | Abstract | Request Reprints |
   
   
9. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Sheehan FH, Braunwald E, Canner P, et al. Circulation 1987;75:817-29.
   | Abstract | Request Reprints |
   
   
10. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Dalen JE, Gore JM, Braunwald E, et al. Am J Cardiol 1988;62:179-85.
    | Abstract | Request Reprints |
    
    
11. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system. Eisenberg PR, Sobel BE, Jaffe AS. Circulation 1988;78:592-7.
    | Abstract | Request Reprints |
    
    
12. Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction. Held AC, Gore JM, Paraskos J, et al. Am J Cardiol 1988;62:310-1.
    | Abstract | Request Reprints |
    
    
13. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Rao AK, Pratt C, Berke A, et al. J Am Coll Cardiol 1988;11:1-11.
    | Abstract | Request Reprints |
    
    
14. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators. Chaitman BR, Thompson B, Wittry MD, et al. J Am Coll Cardiol 1989;14:1159-65.
    | Abstract | Request Reprints |
    
    
15. A physiologically based model of creatine kinase-MB release in reperfusion of acute myocardial infarction. Ong L, Coromilas J, Zimmerman JM, et al. Am J Cardiol 1989;64:11-5.
    | Abstract | Request Reprints |
    
    
16. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Wackers FJ, Terrin ML, Kayden DS, et al. J Am Coll Cardiol 1989;13:998-1005.
    | Abstract | Request Reprints |
    
    
17. Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. Gertz SD, Kalan JM, Kragel AH, Roberts WC, Braunwald E. Am J Cardiol 1990;65:953-61.
    | Abstract | Request Reprints |
    
    
18. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Gertz SD, Kragel AH, Kalan JM, Braunwald E, Roberts WC. Am J Cardiol 1990;66:904-9.
    | Abstract | Request Reprints |
    
    
19. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Habib GB, Heibig J, Forman SA, et al. Circulation 1991;83:739-46.
    | Abstract | Request Reprints |
    
    
20. The consent process in the Thrombolysis in Myocardial Infarction (TIMI--phase I) trial. Ockene IS, Miner J, Shannon TA, Gore JM, Weiner BH, Ball SP. Clin Res 1991;39:13-7.
    | Abstract | Request Reprints |
    
    
21. The rt-PA versus streptokinase. Controversy--II. Braunwald E, Knatterud G, Passamani E. J Am Coll Cardiol 1992;19:1116-9.
    | Abstract | Request Reprints |
    
    
22. Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group. Lehmann KG, Francis CK, Dodge HT. Ann Intern Med 1992;117:10-7.
    | Abstract | Request Reprints |
    
    
23. Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial. Lehmann KG, Francis CK, Sheehan FH, Dodge HT. J Am Coll Cardiol 1993;22:714-9.
    | Abstract | Request Reprints |
    
    
24. Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Thrombolysis in Myocardial Infarction Investigators. McKendall GR, Forman S, Sopko G, Braunwald E, Williams DO. Am J Cardiol 1995;76:1108-11.
    | Abstract | Request Reprints |
    
    
25. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. Kizer JR, Cannon CP, McCabe CH, et al. Am Heart J 1999;137:79-92.
    | Abstract | Request Reprints |
    
    
26. Patient recruitment experience in the Thrombolysis in Myocardial Infarction Trial. Knatterud GL, Forman SA Controlled Clinical Trials 1987;8:86S-93S
    | Abstract | Request Reprints |
    
    
27. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? Flygenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E, for the TIMI investigators. J Am Coll Cardiol 1991;17(Suppl. A):275A.
    | Request Reprints |